ERBB2 and neoplasm: In the ER-positive Her2-positive group at the time of diagnosis (Table 2), patient K76386 developed a ER-positive (weak) Her2-negative component in month 9; and a tumor biopsy performed from patient B62630 in month 49 showed that the tumor was ER-positive Her2-negative (Supplementary Information).